Non-inferiority trials have become an essential instrument in clinical research, particularly when the goal is to demonstrate that an experimental treatment is not unacceptably worse than an ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
A new £50 million initiative aims to cut the length of time novel medicines spend in clinical trials, enabling patients to benefit from new treatments much sooner.
New study findings show that utilizing super-high-pressure non-compliant balloons (NCB) is non-inferior to intravascular lithotripsy (IVL) balloon catheters for lesion preparation and stent expansion ...
TipRanks on MSN
MicroPort NeuroTech steps up competition in brain vascular devices with new embolic agent trial
MicroPort NeuroTech Limited ($HK:2172) announced an update on their ongoing clinical study. Study Overview The clinical study “a Prospective, ...
ONS-5010 shows non-inferiority to Lucentis at 12 weeks; BLA resubmission planned for Q1 2025, with $20.4M in proceeds expected. ONS-5010 demonstrated non-inferiority to ranibizumab at week 12, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback